Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.
Norilsk Nickel with USD 22.36mn ranked first in the Top-15 Russian companies by the value of their intellectual capital. The rating was compiled by the Russian division of the international audit and consulting group Baker Tilly.
Speaking at the International Arctic Forum, the company's senior vice president Larisa Zelkova said: «Traditionally, the company invests in the social structures of the territories where it operates. Over the past five years, we have been actively developing grant and competitive programs in Norilsk and the Kola Peninsula. In addition, the company pays attention to the development of social entrepreneurship - the Academy of Social Entrepreneurship, the provision of interest-free loans for social projects».